ClinicalTrials.gg
RecruitingNCT06943729Updated Aug 29, 2025

Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms

An observational study in Flow Diverter, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Huashan Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
523
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.

Planned enrollment
28th of 51
523 · median 600
Started
2025
with 6 others
Observational
51 of 100
22 open now
Primary completion
2026-12
later than 22 of 41 live
Registered
84th of 100
by date

Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 28th largest by planned enrollment of the 51 observational ones that give a count, is one of 7 that started in 2025, is one of 51 observational ones, reaches primary completion later than 22 of the 41 other live ones, and was the 84th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Intracranial Aneurysm with a site in China, or all of them as a file.
02

Study summary

To collect the safety and effectiveness data of flow-di in the treatment of intracranial aneurysms in real-world clinical practice, verify its classification of treatment strategies for aneurysms of different locations and shapes, and optimize postoperative medication regimen, provide long-term evidence-based basis for clinical treatment of intracranial aneurysms, and build a database.

Read the detailed description

The purpose of this study is to verify the clinical safety and effectiveness of Flow Diverters (FD) in the treatment of intracranial aneurysms. In recent years, FD, as a new type of minimally invasive interventional treatment method, has been widely used in the treatment of various types of intracranial aneurysms. FD promotes the formation of thrombosis in the aneurysm by changing the hemodynamics of the aneurysm, and promotes the repair of vascular endothelium, thereby achieving tumor occlusion. In this study, 523 patients with various types of intracranial aneurysms will be recruited in 36 centers, using a multicenter, prospective, single-arm study design. The main goal of the study was to assess the complete occlusion rate of aneurysms in the 12 months after FD treatment. Secondary goals included postoperative complications (such as cerebral infarction, intracranial thrombosis), postoperative nerve function recovery, and patients' quality of life. At the same time, a large-scale domestic FD database for the treatment of intracranial aneurysms was established. The results of the study will verify the efficacy and safety of FD through clinical imaging evaluation (mainly cerebral angiography) and long-term clinical follow-up data. At the same time, the success rate of surgery and the incidence of restenosis in the stent are analyzed to comprehensively evaluate the application prospects of FD in the treatment of intracranial aneurysms. The results of this study will provide an important evidence-based basis for further promoting the clinical application of FD, optimizing the treatment plan of aneurysms, and improving the patient's prognosis.

03

Conditions studied

  • Flow Diverter

Browse trials for

Keywords

  • Flow Diverter
  • Intracranial Aneurysm
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

intracranial aneurysm diagnosed by CTA, MRA or DSA (Including wide-necked aneurysms (neck width ≥4mm or Dome/neck ratio \<2), saccular, fusiform aneurysms, recurrent saccular aneurysms and dissecting aneurysms, and the diameter of the parent vessel ≥ 2.0 mm and ≤ 6.0 mm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)18 years ≤80 years; 2) intracranial aneurysm diagnosed by CTA, MRA or DSA (Including wide-necked aneurysms (neck width ≥4mm or Dome/neck ratio \<2), saccular, fusiform aneurysms, recurrent saccular aneurysms and dissecting aneurysms, and the diameter of the parent vessel ≥ 2.0 mm and ≤ 6.0 mm; the location includes: anterior circulation C3 segment and above of internal carotid artery, distal artery of Willis circle, posterior circulation V4 segment of vertebral artery and basilar artery and its main branches; 3) Voluntary participation in this study and signing of the Form (ICF).

Exclusion criteria

Exclusion Criteria:

1)AVM related aneurysm; 2) Acute ruptured aneurysm; 3) Severe stenosis or tortuosity of intracranial artery, or anatomical abnormality, which makes it difficult for the device to reach the lesion ; 4) Patients with hemorrhagic or ischemic stroke within 30 days; 5) Modified Rankin Score (mRS)>2 points before operation; 6) Patients with less than 12 months; 7) Patients with definite history of allergy to cobalt-chromium alloy and platinum-tungsten alloy materials; Allergy to contrast media; 8) antiplatelet ()\<100×10\^ 9 /L or/and anticoagulation ; 9) pregnant or lactating women; 10) other study participants who were assessed by the investigator as unsuitable for participation in the study.

Intraoperative exclusion criteria: 1) acute rupture and hemorrhage of aneurysm during operation; 2) failure of FD implantation; 3) thrombosis in stent; 4) stent mal-apposition.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
523 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Aneurysm complete occlusion rate 12 months after surgery

    Time frame: 12 months after surgery

Secondary outcomes

  1. Aneurysm complete occlusion rate 6 months after surgery

    Time frame: 6 months after surgery

  2. Immediate success rate

    Time frame: Immediate

  3. In-stent stenosis (>50% stenosis) rate 6,12 months after surgery

    Time frame: 6,12 months after surgery

  4. Incidence of ipsilateral disabled stroke 3 months after surgery, 6 months after surgery, and 12 months after surgery

    Time frame: 3 months after surgery, 6 months after surgery, and 12 months after surgery

  5. neurogenic death rate 6 months and 12 months after surgery

    Time frame: 6 months and 12 months after surgery

  6. Target aneurysm recurrence retreatment rate 6 months and 12 months after surgery

    Time frame: 6 months and 12 months after surgery

  7. Proportion of study participants with mRS score 0-2

    Time frame: 3 months after surgery, 6 months after surgery, and 12 months after surgery

  8. Incidence of adverse events (AE) and severe adverse events (SAE)

    Time frame: 3 months after surgery, 6 months after surgery, and 12 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 20 months is below that.

Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 24, 2025
StartActual
Apr 27, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943729
Lead sponsor
Huashan Hospital
Collaborators
Xinqiao Hospital of Chongqing, Ningbo No.2 Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Zhengzhou Central Hospital, Xuchang Central Hospital, Second People's Hospital of Hunan, People's Hospital Of Ningxiang City, The First People's Hospital of Changde City, HUANG GANG Central Hospital, Xianning Central Hospital, Jingzhou Central Hospital, Yichang Central People's Hospital, The First People's Hospital of Changzhou, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Northern Jiangsu People's Hospital, Suzhou Municipal Hospital, Jiangsu Taizhou People's Hospital, Huadong Hospital, RenJi Hospital, Shanghai Zhongshan Hospital, Shanghai Fourth People's Hospital, Shanghai Donglei Brain Hospital, Shanghai Pudong New Area People's Hospital, Shanghai East Hospital of Tongji University, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Tangshan Gongren Hospital, The Second Hospital of Hebei Medical University, Hebei General Hospital, Xingtai People's Hospital, Peking University First Hospital, THE AFFILIATED SUZHOU HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL, The Second Affiliated Hospital of Kunming Medical University
Responsible party
Yuxiang Gu (Vice-president of Huashan Hospital west campus, Huashan Hospital) — Principal investigator
First posted
Apr 24, 2025
Start date
Apr 27, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 29, 2025

Study contacts

Gao Chao, PhD
Contact
gc_huashanneuro@sina.com
18916960799
Gu Yuxiang, PhD
study chair · department of Neurosurgery, Huashan Hospital,Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion